David A. Siegel Tango Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $47 Billion
- Q3 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 94,100 shares of TNGX stock, worth $768,797. This represents 0.0% of its overall portfolio holdings.
Number of Shares
94,100Holding current value
$768,797% of portfolio
0.0%Shares
5 transactions
Others Institutions Holding TNGX
# of Institutions
147Shares Held
130MCall Options Held
170KPut Options Held
17.6K-
Trv Gp Iv, LLC Boston, MA13.9MShares$113 Million100.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA10.8MShares$87.9 Million0.39% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA10.6MShares$86.9 Million6.71% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA8.54MShares$69.7 Million8.04% of portfolio
-
Woodline Partners LP San Francisco, CA6.03MShares$49.3 Million0.26% of portfolio
About Tango Therapeutics, Inc.
- Ticker TNGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 88,067,296
- Market Cap $720M
- Description
- Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...